Please check your internet connection and try again.
# Urimax (Tamsulosin)
## Overview
Tamsulosin is a selective alpha-1 adrenergic receptor antagonist that primarily acts on alpha-1A receptors in the prostate and bladder neck, causing smooth muscle relaxation and improving urinary flow.
## Primary Indications
* Treatment of signs and symptoms of benign prostatic hyperplasia (BPH).
* Off-label: Medical expulsion therapy for ureteral stones.
## Adult Dosing
* **BPH:** 0.4 mg orally once daily.
* **Dose Escalation:** If no response after 2–4 weeks, the dose may be increased to 0.8 mg orally once daily.
* **Timing:** Administer approximately 30 minutes after the same meal each day to improve bioavailability.
## Pediatric Dosing
* **Safety/Efficacy:** Not FDA-approved for pediatric use.
* **Off-label use:** Use is rare and limited to specialized pediatric urology settings (e.g., neurogenic bladder). Dosing is highly variable and weight-based; consult institutional protocols or pediatric specialty guidelines.
## Dose Adjustments
* **Renal Impairment:** No initial dosage adjustment required.
* **Hepatic Impairment:** Use with caution in severe hepatic impairment (Child-Pugh class C). No specific dosage adjustment available.
* **CYP3A4 Inhibitors:** May require dose reduction or avoidance if used with strong inhibitors (e.g., ketoconazole).
## Contraindications
* Hypersensitivity to tamsulosin.
* Concomitant use of strong CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole).
## Adverse Effects
* **Common:** Dizziness, headache, abnormal ejaculation (retrograde), rhinitis, asthenia.
* **Serious:** Orthostatic hypotension (syncope), priapism, Intraoperative Floppy Iris Syndrome (IFIS) during cataract surgery.
## Key Drug Interactions
* **PDE-5 Inhibitors:** Concomitant use with drugs like sildenafil or tadalafil may lead to symptomatic hypotension.
* **Antihypertensives:** Potential for additive blood pressure lowering effects.
* **CYP3A4/2D6 Inhibitors:** Increased serum concentrations possible when combined with inhibitors like paroxetine or ritonavir.
## Monitoring
* Monitor for orthostatic hypotension, especially after the first dose or during dose titration.
* Assess for BPH symptom improvement (e.g., AUA Symptom Score).
* Screen for history of cataract surgery or planning for upcoming cataract surgery.
## Clinical Pearls
* **IFIS:** Inform patients planning cataract surgery to notify their ophthalmologist that they are taking or have previously taken tamsulosin.
* **Administration:** Swallow the capsule whole. Do not crush or chew, as this disrupts the extended-release matrix.
* **Syncope:** Advise patients to rise slowly from a sitting or lying position, particularly during initiation.
***
**Disclaimer:** This information is for educational purposes only. Always verify current prescribing information, contraindications, and local institutional protocols, as clinical guidelines and formulation-specific data may change. Consult a physician or pharmacist before making clinical decisions.
